MicroPort Scientific (853) H2 2024 earnings summary

Executive summary

• Revenue reached $1,031.1 million, up 10% year-over-year, with non-China sales at 49.5% of total and significant overseas growth.

• Net loss narrowed 59% to $268.5 million, and EBITDA turned positive at $60.4 million from a $370.4 million loss.

• Overseas business revenue surged 84.7% year-over-year (ex-FX), with robust commercialization across 100+ countries.

• Cost controls and resource prioritization led to a 24% drop in total distribution, admin, and R&D expenses.

• No final dividend proposed for 2024.

Financial highlights

• Gross profit increased 7.9% to $574.1 million; gross margin slightly decreased to 55.7%.

• Operating expenses decreased significantly, with R&D costs down 42.9%, distribution costs down 9.2%, and administrative expenses down 11.3% year-over-year.

• Finance costs rose 10.8% to $106.4 million.

• Adjusted net loss (non-HKFRS) was $222.8 million, down 48.7% year-over-year.

• Cash and cash equivalents at year-end: $713.0 million (down from $1,019.6 million); net current assets: $558.3 million.

Outlook and guidance

• Continued focus on global expansion, innovation, and commercialization of new products.

• Strategic investments in R&D and product pipeline expected to drive future growth.

• Global medical device demand expected to rise with aging populations and higher health awareness.

• Short-term risks include macroeconomic uncertainty, intensified competition, and regulatory changes in China.

• Focus remains on core business, cost control, global expansion, and innovation to drive profitability.